Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Ariad Pharm Inc (ARIA) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,555,690
  • Shares Outstanding, K 192,710
  • Annual Sales, $ 118,800 K
  • Annual Income, $ -231,160 K
  • 36-Month Beta 2.11
  • Price/Sales 21.51
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.03 +49.39%
on 11/08/16
14.42 -6.45%
on 11/29/16
+4.61 (+51.91%)
since 11/04/16
3-Month
8.63 +56.32%
on 11/03/16
14.42 -6.45%
on 11/29/16
+3.08 (+29.59%)
since 09/06/16
52-Week
4.37 +208.70%
on 02/11/16
14.42 -6.45%
on 11/29/16
+7.62 (+129.81%)
since 12/04/15

Most Recent Stories

More News
New Collaborations and Licensing Activities for Biotech/Pharma Industries Pick Up Pace Heading into 2017

Biotech and Big Pharma companies focus on forging ahead with developing pipeline candidates and licensing opportunities that appear to bea promising opportunity versus developing therapy products from...

ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated...

Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno

With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?

New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day

New Oriental Education & Technology Group, BJ’s Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day

3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise

Will a Trump presidency trigger more M&A deals in the biotech sector?

ARIAD Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month

--Launch of patient and caregiver website, www.livingwithALK.com

Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now

With pharma and biotech stocks reacting favorably to Trump's win, it looks like a good time to invest in this sector.

ARIAD Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology

--~In crizotinib-naive ALK+ NSCLC patients, eight of eight patients had a confirmed response

ARIAD (ARIA) Stock Up on Narrower-than-Expected Q3 Loss

ARIAD (ARIA) reported third-quarter 2016 loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 29 cents. Higher U.S. Iclusig sales and lower...

Ariad Pharmaceuticals Down 21.2% Since SmarTrend Downtrend Call (ARIA)

SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 14th, 2016 at $12.19. In approximately 3 weeks, Ariad Pharmaceuticals has returned 21.16% as of today's recent price...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and...

See More

Support & Resistance

2nd Resistance Point 13.64
1st Resistance Point 13.46
Last Price 13.58
1st Support Level 13.10
2nd Support Level 12.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.